SUSRF Stock Chart & Stats
$3.12
-$0.02(-0.64%)
―
--
Day’s Range― - ―
52-Week Range$2.58 - $16.84
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$162.66M
Enterprise Value$884.60
Total Cash (Recent Filing)$667.73M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)29.3
Beta0.38
Next Earnings
Aug 19, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.03
Shares Outstanding51,026,237
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.39
Price to Sales (P/S)1.67
P/FCF Ratio24.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.21
Revenue Forecast (FY)$102.50M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNear-zero debt and substantial net cash (net cash SEK 668m noted elsewhere) give durable financial flexibility. This supports multi-quarter investment in R&D, pricing discipline, and absorption of FX or timing shocks without forcing asset sales or dilution, preserving strategic optionality.
Cash Generation ReboundRebounding operating and free cash flow indicate the business is converting underlying sales into liquidity. Persistent positive cash generation underpins reinvestment in product development and production scale-ups, and reduces reliance on external funding over the medium term.
Diversified Product & Robotics PipelineExpanding robotics partnerships and broader product launches (ultrasound, shared platform modules) reduce single-customer concentration and create multiple licensing opportunities. This structural diversification supports multi-year revenue potential and reduces sensitivity to any one partner.
Bears Say
Intuitive License Revenue ReversionA known SEK 60–90m headwind to 2026 license revenues is a material, multi-quarter revenue shortfall. It reduces near-term cash and operating leverage, forcing management to rely on other product wins and margin actions to preserve profitability until replacement contracts or new customers scale.
Margin Compression And Weaker ProfitabilitySignificant compression from prior-year margins means the firm currently earns lower returns on sales. Sustained lower operating/net margins constrain free cash flow generation and return on invested capital, requiring either structural cost reductions or consistent higher revenue growth to restore prior profitability.
Structural Headwinds In ChinaPolicy-backed local competitors in China create a durable market-share and pricing challenge. This structural disadvantage can depress growth in a major region, force increased local investment or partnerships, and lengthen the timetable to rebuild momentum in APAC absent a tailored strategy.
Surgical Science Sweden AB News
SUSRF FAQ
What was Surgical Science Sweden AB’s price range in the past 12 months?
Surgical Science Sweden AB lowest stock price was $2.58 and its highest was $16.84 in the past 12 months.
What is Surgical Science Sweden AB’s market cap?
Surgical Science Sweden AB’s market cap is $162.66M.
When is Surgical Science Sweden AB’s upcoming earnings report date?
Surgical Science Sweden AB’s upcoming earnings report date is Aug 19, 2026 which is in 33 days.
How were Surgical Science Sweden AB’s earnings last quarter?
Surgical Science Sweden AB released its earnings results on May 20, 2026. The company reported $0.038 earnings per share for the quarter, beating the consensus estimate of $0.032 by $0.007.
Is Surgical Science Sweden AB overvalued?
According to Wall Street analysts Surgical Science Sweden AB’s price is currently Undervalued.
Does Surgical Science Sweden AB pay dividends?
Surgical Science Sweden AB does not currently pay dividends.
What is Surgical Science Sweden AB’s EPS estimate?
Surgical Science Sweden AB’s EPS estimate is 0.04.
How many shares outstanding does Surgical Science Sweden AB have?
Surgical Science Sweden AB has 51,026,237 shares outstanding.
What happened to Surgical Science Sweden AB’s price movement after its last earnings report?
Surgical Science Sweden AB reported an EPS of $0.038 in its last earnings report, beating expectations of $0.032. Following the earnings report the stock price went up 49.817%.
Which hedge fund is a major shareholder of Surgical Science Sweden AB?
Currently, no hedge funds are holding shares in SUSRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Science Sweden AB
Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.
Ownership Overview
―
Insiders
<0.01% Mutual Funds
― Other Institutional Investors
99.92% Public Companies and
Individual Investors